A trial looking at treatment for haemophagocytic lymphohistiocytosis (HLH) in children and young people (HLH 2004)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Children's cancers

Status:

Results

Phase:

Phase 3

This trial looked at initial treatment for children and young people with haemophagocytic lymphohistiocytosis (HLH).

More about this trial

HLH is a rare condition where the body produces too many white blood cells called lymphocytes and histiocytes. If it is not treated, these extra cells collect in organs in the body and damage them. HLH is not cancer, but it is similar to cancer and usually treated by cancer specialists. 
 
There are two different forms of HLH:
  • primary HLH develops because of an inherited genetic change (mutation)
  • secondary HLH develops because of a problem with the immune system such as an infection
 
A trial called HLH 94 looked at treatment with etoposide chemotherapy and the steroid dexamethasone to begin with (initial therapy). And then etoposide, dexamethasone and cyclosporin after that (continuation therapy). Cyclosporin is a drug that dampens down the immune system.
 
This treatment works quite well, but doctors hoped that having etoposide, dexamethasone and cyclosporin together from the beginning may be better. 
 
The aim of the HLH 2004 trial was to find out how well etoposide, dexamethasone and cyclosporin work as initial treatment for primary and secondary HLH.

Summary of results

This trial showed that having etoposide, dexamethasone and cyclosporin as initial treatment was not better for people with haemophagocytic lymphohistiocytosis (HLH).
 
This trial recruited patients between 2004 and 2011, and the results were reported in 2017.
 
Results
The trial recruited 369 children and young people from 27 different countries. Of those taking part:
  • 168 had primary HLH
  • 201 had secondary HLH
Everyone taking part had etoposide, dexamethasone and cyclosporin as initial treatment. Some people went on to have a stem cell transplant.
 
The research team looked at how many people were living 5 years after joining the trial. They found it was just over 6 out of 10 people (61%). When they looked at the different types of HLH they found it was:
  • just under 6 out of 10 people (59%) who had primary HLH
  • more than 6 out of 10 people (64%) who had secondary HLH
The number of people living at 5 years in the HLH 94 trial was more than 5 out of 10 (54%). So there was not much difference between the two.
 
Of the 188 people who went on to have a stem cell transplant, 121 (66%) lived for at least 5 years. This is the same percentage as the HLH 94 trial.
 
Side effects
The treatments used in this trial have all been used to treat cancer, and other conditions, for a number of years. The people taking part in this trial didn’t have any unexpected side effects.
 
A few people had serious side effects such as:
  • problems with the brain which may cause fits or learning difficulties
  • problems caused by high blood pressure
  • liver problems
  • infections
One person went on to develop acute myeloid leukaemia (AML).
 
Conclusion
The trial team concluded that it was not better to include cyclosporin in initial treatment for HLH. They recommend that children and young adults with HLH continue to have etoposide and dexamethasone at the start of treatment.
 
They suggest that it might be useful to look at other treatments alongside standard treatment. This could include monoclonal antibodies or other targeted drugs.
 
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Vasanta Nanduri

Supported by

Cancer Research UK Children's Cancer Trials Team
University of Birmingham
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

767

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Katie took part in a new clinical trial

A picture of Katie cycling

"We believed that with the clinical trial, Katie had the best chance of recovery. Without these trials, amazing new treatments may never be found."

Last reviewed:

Rate this page:

Currently rated: 3.3 out of 5 based on 45 votes
Thank you!
We've recently made some changes to the site, tell us what you think